Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 3, 2007, Pages 122-130

  Shinozaki, Kazuya ^a   Nishio, Yoshihiko ^a   Ayajiki, Kazuhide ^a   Yoshida, Yuichi ^b   Masada, Masahiro ^b   Kashiwagi, Atsunori ^a   Okamura, Tomio ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

3 hydroxyl 3 methylglutaryl coenzyme A reductase inhibitors; Angiotensin II; Endothelium; Insulin resistance; Nitric oxide; Tetrahydrobiopterin

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; PITAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; TETRAHYDROBIOPTERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; INSULIN RESISTANCE; ISOLATED ARTERY; LEAN BODY WEIGHT; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TREATMENT DURATION; VASOCONSTRICTION; ZUCKER RAT;

ANGIOTENSIN II; ANIMALS; AORTA; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GTP CYCLOHYDROLASE; INSULIN RESISTANCE; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; QUINOLINES; RATS; RATS, ZUCKER; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDES;

EID: 34147203072     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802f5895     Document Type: Article

References (43)

1. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:702-706.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
3. Laakso M, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991;11:1068-1076.
4. Shinozaki K, Suzuki M, Ikebuchi M, et al. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation. 1995;92:1749-1757.
5. Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in aortas of insulin-resistant rats. Circ Res. 2000;87:566-573.
6. Shinozaki K, Hirayama A, Nishio Y, et al. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol. 2001;38:1821-1828.
7. Gopaul NK, Manraj MD, Hebe A, et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia. 2001;44:706-712.
8. - imbalance in insulin-resistant rat aorta. Diabetes. 1999;48:2437-2445.
9. Shinozaki K, Ayajiki K, Nishio Y, et al. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension. 2004;43:255-262.
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
11. Long-Term Intervention with Pravastatin in Ischemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
13. Keech A, Colquhoun D, Best J, et al. LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713-2721.
14. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
15. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-654.
16. Kajinami K, Mabuchi H, Saito Y. NK-104: a novel synthetic HMG-CoA redutase inhibitor. Exp Opin Invest Drugs. 2000;9:2653-2661.
17. Hesslinger C, Kremmer E, Hultner L, et al. Phosphorylation of GTP cyclohydrolase I and modulation of its activity in rodent mast cells. GTP cyclohydrolase I hyperphosphorylation is coupled to high affinity IgE receptor signaling and involves protein kinase C. J Biol Chem. 1998;273:21616-21622.
18. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol. 1973;34:279-282.
19. Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in aortas of insulin-resistant rats. Circ Res. 2000;87:566-573.
20. Li Y, Zhu H, Kuppusamy P, et al. Validation of lucigenin (Bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem. 1998;273:2105-2123.
21. G-nitro-L-arginine in isolated dog and monkey cerebral arteries. Stroke. 1993;24:1584-1589.
22. Masada M, Akino M, Sueoka T, et al. Dyspropterin, an intermediate formed drom dihydroneopterin triphosphate in the biosynthetic pathway of tetrahydrobiopterin. Biochim Biophys Acta. 1985;840:235-244.
23. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
24. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA. 1989;86:9717-9721.
25. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
26. Reif A, Fršhlich LG, Kotsonis P, et al. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem. 1999;274:24921-24929.
27. Wermer ER, Werner-Felmayer G, Wachter H, et al. Biosynthesis of nitric oxide: dependence on pteridine metabolism. Rev Physiol Biochem Pharmacol. 1995;127:97-135.
28. Kontos HA, Kontos MC. Role of products of univalent reduction of oxygen in hypertensive vascular injury. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press; 1995;685-696.
29. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest. 1982;47:412-425.
30. Kaufman S, Kapatos G, Rizzo WB, et al. Tetrahydropterin therapy for hyperphenylalaninemia caused by defective synthesis of tetrahydrobiopterin. Ann Neurol. 1983;14:308-315.
31. Cai S, Khoo J,Channon KM. Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res. 2005;65:823-831.
32. Zheng JS, Yang XQ, Lookingland KJ, et al. Gene transfer of human guanosine 5-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation. 2003:108:1238-1245.
33. Shinozaki K, Nishio Y, Yoshida Y, et al. Supplement of tetrahydrobiopterin by a gene transfer of GTP cyclohydrolase I cDNA improves vascular dysfunction in insulin-resistant rats. J Cardiovasc Pharmacol. 2005,46:505-512.
34. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
35. Hattori Y, Nakanishi N, Akimoto K, et al. HMG-CoA reductase inhibitor increases GTP-cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:176-182.
36. Klatt P, Schmid M, Leopold E, et al. The pteridine binding site of brain nitric oxide synthase. Tetrahydrobiopterin binding kinetics, specificity, and allosteric interaction with the substrate domain. J Biol Chem. 1994;269:13861-13866.
37. Shinozaki K, Kashiwagi A, Masada M, et al. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord. 2004;4:1-11.
38. Kuzkaya N, Weissmann N, Harrison DG, et al. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem. 2003;278:22546-22554.
39. Wang X, Nickenig G, Murphy TJ. The vascular smooth muscle type I angiotensin II receptor mRNA is destabilized by cyclic AMP-elevating agents. Mol Pharmacol. 1997;52:781-787.
40. Nickenig G, Roling J, Strehlow K, et al. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation. 1998;98:2453-2460.
41. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
42. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
43. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 1993;21:1145-1151.